Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors of immunotherapy in metastatic renal cell carcinoma

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The prognosis of the majority of patients with metastatic renal cell carcinoma is poor, and there is no internationally recognized standard therapy for these patients. Patients are treated with interferon alpha or interleukin-2 monotherapy, or combinations outside of clinical trials and a subgroup of patients responds to these therapies. Because immunotherapy induces adverse effects in almost every patient, it is necessary to avoid treating patients who will not, in the end, benefit from the treatment. It is therefore sensible to carefully select patients prior to the initiation of immunotherapy. Determining prognostic factors of survival or of rapid progression under treatment would be of help for selecting patients for immunotherapy. This article reviews current data about prognostic and predictive factors from immunotherapy studies in metastatic renal cell carcinoma comparing all analyzed factors with those that demonstrated an independent prognostic significance in multivariate analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533–543.

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49:33–64.

    Article  PubMed  CAS  Google Scholar 

  3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611–1623.

    Article  PubMed  CAS  Google Scholar 

  4. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691–1696.

    Article  PubMed  CAS  Google Scholar 

  5. Savage PD. Renal cell carcinoma. Curr Opin Oncol 1996; 8:247–251.

    Article  PubMed  CAS  Google Scholar 

  6. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865–875.

    Article  PubMed  CAS  Google Scholar 

  7. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995; 22:42–60.

    PubMed  CAS  Google Scholar 

  8. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19:1541–1543.

    PubMed  CAS  Google Scholar 

  9. Motzer RJ. Renal cell carcinoma: progress against an elusive tumor. Semin Oncol 2000; 27:113–114.

    PubMed  CAS  Google Scholar 

  10. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27:177–186.

    PubMed  CAS  Google Scholar 

  11. Pyrhönen S, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859–2867.

    PubMed  Google Scholar 

  12. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353:14–17.

  13. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27:187–193.

    PubMed  CAS  Google Scholar 

  14. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6:S55–57.

    PubMed  Google Scholar 

  15. Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688–696.

    PubMed  CAS  Google Scholar 

  16. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000:CD001425.

  17. Negrier S, et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000; 6:S93–98.

    PubMed  Google Scholar 

  18. Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000; 27:204–212.

    PubMed  CAS  Google Scholar 

  19. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19:148–154.

    PubMed  CAS  Google Scholar 

  20. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136:376–379.

    PubMed  CAS  Google Scholar 

  21. de Forges A, et al. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 1988; 4:149–154.

    Article  PubMed  Google Scholar 

  22. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310–7313.

    PubMed  CAS  Google Scholar 

  23. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994; 30A:1310–1314.

    Article  PubMed  CAS  Google Scholar 

  24. Fossa S, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995; 76:286–290.

    PubMed  CAS  Google Scholar 

  25. Citterio G, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997; 31:286–291.

    PubMed  CAS  Google Scholar 

  26. Takashi M, Kawai T, Murase T, Wakai K, Ohno Y. Multivariate evaluation of prognostic determinants for renal cell carcinomas which are metastatic at initial diagnosis. Int Urol Nephrol 1997; 29:291–300.

    Article  PubMed  CAS  Google Scholar 

  27. Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530–2540.

    PubMed  CAS  Google Scholar 

  28. Motzer RJ, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:1928–1935.

    PubMed  CAS  Google Scholar 

  29. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000; 34:246–251.

    Article  PubMed  CAS  Google Scholar 

  30. Palmer PA, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3:475–480.

    PubMed  CAS  Google Scholar 

  31. Jones M, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993; 8:275–288.

    PubMed  CAS  Google Scholar 

  32. Lissoni P, et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 1994; 51:59–62.

    Article  PubMed  CAS  Google Scholar 

  33. Canobbio L, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. J Cancer Res Clin Oncol 1995; 121:753–756.

    Article  PubMed  CAS  Google Scholar 

  34. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:35–40.

    Article  PubMed  CAS  Google Scholar 

  35. Lopez Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155:19–25.

    Article  PubMed  Google Scholar 

  36. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289–296.

    Article  PubMed  CAS  Google Scholar 

  37. Negrier S, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie. Ann Oncol 2002; 13:1460–1468.

    Article  PubMed  CAS  Google Scholar 

  38. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348–353.

    Article  PubMed  CAS  Google Scholar 

  39. Elias L, Hunt WC. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy. Oncology 2001; 61:91–101.

    Article  PubMed  CAS  Google Scholar 

  40. Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655–1659.

    Article  PubMed  CAS  Google Scholar 

  41. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966–970.

    Article  PubMed  CAS  Google Scholar 

  42. Mian BM, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167:65–70.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic of Hematology & Oncology, Tartu University Clinics, Vallikraavi 7, 51003, Tartu, Estonia

    Peeter Padrik

Authors
  1. Peeter Padrik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peeter Padrik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padrik, P. Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 20, 325–334 (2003). https://doi.org/10.1385/MO:20:4:325

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:20:4:325

Key Words

Search

Navigation